海思科：HSK3.9万吸入粉雾剂IND申请获受理

美港电讯11-06

【海思科：HSK3.9万吸入粉雾剂IND申请获受理】金十数据11月6日讯，海思科公告，公司子公司西藏海思科制药有限公司和四川海思科制药有限公司近日收到国家药品监督管理局下发的《受理通知书》，涉及创新药HSK3.9万吸入粉雾剂。该药品为公司自主研发的靶向小分子抑制剂，拟用于慢性阻塞性肺疾病的治疗。HSK3.9万吸入粉雾剂在临床前研究中显示出显著的气道舒张和抗炎作用，且具备良好的安全性。此次申请的受理...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2481629935?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-06 16:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481629935","market":"hk","top_or_hot":-1,"title":"海思科：HSK3.9万吸入粉雾剂IND申请获受理","media":"美港电讯","content":"<div>\n<p>【海思科：HSK3.9万吸入粉雾剂IND申请获受理】金十数据11月6日讯，海思科公告，公司子公司西藏海思科制药有限公司和四川海思科制药有限公司近日收到国家药品监督管理局下发的《受理通知书》，涉及创新药HSK3.9万吸入粉雾剂。该药品为公司自主研发的靶向小分子抑制剂，拟用于慢性阻塞性肺疾病的治疗。HSK3.9万吸入粉雾剂在临床前研究中显示出显著的气道舒张和抗炎作用，且具备良好的安全性。此次申请的受理...</p>\n\n<a href=\"https://www.ushknews.com/\">网页链接</a>\n\n</div>\n","source":"live_meigang","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>海思科：HSK3.9万吸入粉雾剂IND申请获受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n海思科：HSK3.9万吸入粉雾剂IND申请获受理\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-06 16:50 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.ushknews.com/><strong>美港电讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>【海思科：HSK3.9万吸入粉雾剂IND申请获受理】金十数据11月6日讯，海思科公告，公司子公司西藏海思科制药有限公司和四川海思科制药有限公司近日收到国家药品监督管理局下发的《受理通知书》，涉及创新药HSK3.9万吸入粉雾剂。该药品为公司自主研发的靶向小分子抑制剂，拟用于慢性阻塞性肺疾病的治疗。HSK3.9万吸入粉雾剂在临床前研究中显示出显著的气道舒张和抗炎作用，且具备良好的安全性。此次申请的受理...</p>\n\n<a href=\"https://www.ushknews.com/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"https://www.ushknews.com/","article_id":"2481629935","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481629935","pubTimestamp":1730883005,"columns":[],"sourceInfo":{"source_id":"live_meigang","name":"美港电讯"},"weMediaInfo":null,"summary":"【海思科：HSK3.9万吸入粉雾剂IND申请获受理】金十数据11月6日讯，海思科公告，公司子公司西藏海思科制药有限公司和四川海思科制药有限公司近日收到国家药品监督管理局下发的《受理通知书》，涉及创新药","collect":0,"end_time":0,"defaultTopTitle":"ushknews.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159992":"创新药","BK0239":"医药制造","BK1583":"高瓴概念","BK0077":"质押式回购","002653":"海思科","01477":"欧康维视生物-B","BK1191":"制药","BK1161":"生物科技","03347":"泰格医药","BK0188":"融资融券","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","BK0033":"西藏振兴","06978":"永泰生物-B","BK1574":"生物医药B类股","BK0028":"国家队"},"translate_title":"Haisco: HSK 39,000 inhalation powder IND application accepted","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"002653":1,"01477":1,"03347":1,"06978":1},"content_text":"【海思科：HSK3.9万吸入粉雾剂IND申请获受理】金十数据11月6日讯，海思科公告，公司子公司西藏海思科制药有限公司和四川海思科制药有限公司近日收到国家药品监督管理局下发的《受理通知书》，涉及创新药HSK3.9万吸入粉雾剂。该药品为公司自主研发的靶向小分子抑制剂，拟用于慢性阻塞性肺疾病的治疗。HSK3.9万吸入粉雾剂在临床前研究中显示出显著的气道舒张和抗炎作用，且具备良好的安全性。此次申请的受理意味着该药品将进入境内生产药品注册临床试验阶段，有望为慢性阻塞性肺疾病患者提供新的治疗方案。","kind":"live","is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481629935"}